SS-31 is elamipretide, FDA-approved as Forzinity only for Barth syndrome. What it does, what trials show about benefits and side effects, and 2026 status.
PeptIQ Team
Peptide Research & Education
PeptIQ app
Track your peptide protocols in PeptIQ
Log injections, vial supply, and reminders. Use peptiq.io calculators when you need math on the web.
SS-31 is elamipretide, a small lab-made peptide that sticks to cardiolipin, a fat found in the inner membrane of mitochondria. It is one of the rare "research peptides" that became an approved medicine:
FDA approved it on September 19, 2025 as Forzinity, under accelerated approval, for one rare genetic disease: Barth syndrome. The approval is based on stronger knee muscles, and FDA requires a confirmatory trial. That trial started in July 2026.
Outside Barth syndrome, the controlled trials mostly missed their main goals. That includes primary mitochondrial myopathy, heart failure, dry macular degeneration and a rare eye disease. A Phase 3 trial in dry macular degeneration is still running.
The most common side effect is an injection-site reaction. The label also warns about serious allergic reactions.
"SS-31" vials sold online are not Forzinity. FDA called them unapproved new drugs in an August 2026 warning letter. SS-31 is not one of the six peptides in the October 30, 2026 HHS compounding policy.
This PeptIQ.io guide was updated on November 6, 2026 from the FDA label, PubMed and ClinicalTrials.gov. It contains no dosing information.
Talk to a licensed clinician before using SS-31 or any product sold as SS-31.
What Is SS-31 Peptide?
SS-31 is a tetrapeptide, a chain of just four amino acids. The "SS" stands for Szeto-Schiller, after the researchers who developed this family of peptides. Over the years it has carried several names:
SS-31 (or SS31), the original research name
MTP-131 and Bendavia, names used in early company trials
Elamipretide, the official drug name
Forzinity, the brand name of the FDA-approved injection made by Stealth BioTherapeutics
All of these refer to the same molecule. When you see "ss31 peptide" in a forum post and "elamipretide" in a medical journal, they are the same thing.
PeptIQ.io / SS-31 / 01
One molecule, five names.
SS-31, MTP-131, Bendavia, elamipretide and Forzinity all refer to the same peptide. Here is what it is designed to do.
Research name
SS-31
Trial names
MTP-131 / Bendavia
Drug name
Elamipretide
Rx brand
Forzinity
1
Enters
Into cells
A four-amino-acid peptide small enough to cross cell membranes.
2
Collects
Inner mitochondrial membrane
Where the energy-making machinery sits.
3
Binds
Cardiolipin
A fat that holds that machinery together. Abnormal in Barth syndrome.
Evidence, not marketing.Nov 2026
Names from ClinicalTrials.gov records and the FDA label. Mechanism from the Forzinity prescribing information (section 12.1) and Szeto, Br J Pharmacol 2014 (PubMed 24117165). A mechanism is not proof of benefit.
How SS-31 Works: Cardiolipin
Mitochondria are the parts of a cell that turn food into usable energy. Their inner membrane holds the energy-making machinery, and a fat called cardiolipin helps keep that machinery folded and working. When cardiolipin is damaged or abnormal, energy production suffers.
SS-31 was designed to move into cells, collect at the inner mitochondrial membrane and bind cardiolipin. In a 2014 review, Szeto described it as a "cardiolipin-protective compound" meant to restore mitochondrial energy production. The Forzinity label puts it more plainly. It calls the drug a "mitochondrial cardiolipin binder" that "localizes to the inner mitochondrial membrane and improves mitochondrial morphology and function."
That is why Barth syndrome was such a good fit. The disease is caused by changes in the TAZ gene, which leaves people with abnormal cardiolipin. The drug's target is the disease's core problem.
A strong mechanism is not proof of benefit, though. As the trials below show, fixing mitochondria in a dish does not guarantee that people walk farther or feel less tired.
SS-31 Benefits: What the Trials Actually Show
SS-31 has a much bigger human evidence base than most peptides discussed online. ClinicalTrials.gov lists about 20 elamipretide studies since 2012, many of them randomized and placebo-controlled. That makes it possible to say fairly clearly where it has worked and where it has not.
Barth syndrome: approved, with caveats. The TAZPOWER trial enrolled 12 people with Barth syndrome. In its 12-week placebo-controlled crossover phase, neither primary endpoint was met (walking distance and a symptom score). In the open-label extension that followed, where everyone knew they were getting the drug, walking distance and symptoms improved. A 168-week follow-up reported continued gains in the 8 people who stayed in the study. FDA based its accelerated approval on improved strength of the knee extensor muscle (the one that straightens the leg). FDA considers this "reasonably likely to predict patient benefit," and it requires a confirmatory randomized trial. That trial (NCT07531251) began recruiting in July 2026 and lists primary completion in September 2029.
Primary mitochondrial myopathy: missed.MMPOWER-3, published in Neurology in 2023, randomized 218 adults. After 24 weeks, walking distance and fatigue scores were no better than with placebo. A separate Phase 3 trial in people whose disease comes from nuclear DNA changes, NuPower (NCT05162768), finished in September 2024. It has no results posted on ClinicalTrials.gov as of November 6, 2026.
Heart failure: missed. In the PROGRESS-HF Phase 2 trial, four weeks of elamipretide did not improve heart size or pumping function compared with placebo in people with heart failure with reduced ejection fraction.
Dry macular degeneration: mixed, still being tested. The ReCLAIM-2 Phase 2 trial in 176 people did not meet its primary endpoints for vision or lesion growth. It did show slower loss of a retina layer linked to the light-sensing cells. A Phase 3 trial, ReNEW (NCT06373731), enrolled 313 people and expects primary completion in August 2027.
Leber hereditary optic neuropathy: missed. A small trial of an elamipretide eye drop (Ophthalmology, 2024) found no difference from the vehicle drop in visual acuity.
Healthy aging: early signals only. In a 2021 randomized trial of 39 older adults with poorly functioning muscle mitochondria, a single infusion raised muscle energy capacity right afterward. The effect was gone a week later, and muscle fatigue did not change. A small open-label pilot in older adults (NCT07275424) is measuring safety and has no results yet.
PeptIQ.io / SS-31 / 02
Approved for one disease. Missed in most others.
SS-31 has more human trials than most peptides. The scorecard is what the energy and anti-aging claims leave out.
Barth syndrome
TAZPOWER, then accelerated approval on knee strength. Confirmatory trial recruiting.
Approved
Dry macular degeneration
ReCLAIM-2 missed its primary endpoints. Phase 3 ReNEW results expected after Aug 2027.
Pending
Mitochondrial myopathy
MMPOWER-3 (218 adults) missed. NuPower finished in 2024 with no posted results.
Missed
Heart failure
PROGRESS-HF: no change in heart size or pumping function versus placebo.
Missed
Rare eye disease (LHON)
Eye-drop trial: no difference from vehicle in visual acuity.
Missed
Healthy aging
One infusion briefly raised muscle energy capacity, with no change in fatigue. Pilot ongoing.
So the claims you see for SS-31, such as more energy, anti-aging, heart support, sharper focus and better endurance, are not what the controlled trials found. The approved benefit is stronger knee muscles in Barth syndrome. A 2026 drug profile in Drugs notes that elamipretide is still in Phase 3 development for dry macular degeneration and mitochondrial myopathies, so the picture could change. For now, it has not been shown to boost mitochondria in general.
SS-31 Side Effects and Safety
Because Forzinity is an approved drug, its side effects are documented on an FDA label, which is not true of most peptides. From the prescribing information:
Injection-site reactions are the most common side effect. In the placebo-controlled Barth trial, all 12 people had at least one local reaction on the drug, compared with 8 of 12 on placebo. These included redness, pain, hardening, itching, bruising and hives at the injection site.
Serious allergic reactions have been reported, including some that needed emergency care. They can start "within minutes to months" after treatment begins. Serious hypersensitivity to the drug is a contraindication.
Eosinophil counts often rise. These are a type of white blood cell. The increase usually peaked around three months and settled over time, without symptoms.
The kidneys clear it. The label says nearly all of a dose shows up in the urine within 48 hours, and exposure is higher in people with reduced kidney function. The label adjusts treatment for severe kidney impairment.
It contains benzyl alcohol as a preservative and should not be used in newborns.
Other trials report a similar pattern. In ReCLAIM-2, adverse events affected 86% of the elamipretide group versus 71% on placebo, mostly injection-site reactions.
What about SS-31 half-life? The label does not give a half-life. It does say the drug peaks in the blood within about an hour of an injection under the skin and is cleared through the kidneys within about two days. Figures quoted on vendor sites do not describe how an untested vial behaves.
Is SS-31 FDA Approved or Legal in 2026?
Yes, but only as Forzinity, and only for Barth syndrome. The label's indication is "to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg." That is the only approved use. FDA has not approved it for aging, energy, heart failure, eye disease or athletic performance.
PeptIQ.io / SS-31 / 03
Forzinity is not a research vial.
Same molecule on paper, very different products. This is what separates the approved drug from SS-31 sold online.
QuestionForzinity (Rx)“SS-31” research vial
FDA approved?
Forzinity:Yes, Sept 2025, accelerated approval
Research vial:No. FDA calls these unapproved new drugs
Approved use
Forzinity:Muscle strength in Barth syndrome only
Research vial:None
Identity, purity, sterility
Forzinity:Checked against FDA standards
Research vial:Not verified by any regulator
Side effects documented
Forzinity:On the FDA label
Research vial:Unknown for the specific product
In the Oct 2026 HHS policy?
Forzinity:Not needed. It is an approved drug
Research vial:No. SS-31 is not in Appendix A
Evidence, not marketing.Nov 2026
Sources: FDA approval announcement (September 19, 2025) and Forzinity prescribing information; FDA warning letter to Royal Peptides LLC (August 24, 2026); HHS enforcement discretion policy, Appendix A (Federal Register 2026-22192, October 30, 2026). Not legal advice.
Products sold as "SS-31" are a different matter:
Research-use vials. In an August 24, 2026 warning letter, FDA listed "SS-31 (Elamipretide)" among products it called "unapproved new drugs," despite the seller's research-only framing. A research vial has no FDA check on identity, purity or sterility.
The October 2026 HHS policy. On October 30, 2026, HHS published an interim enforcement discretion policy for compounding certain peptides. SS-31 is not one of the six peptides in Appendix A, which lists BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. That policy does not cover SS-31.
Telehealth programs. Some online clinics market physician-prescribed SS-31. One example is ss-31.com, an SS-31 brand in the meds.you portfolio. If you look at a program like this, compare its benefit claims with the trial results above, and ask whether you would get Forzinity or a compounded product, which pharmacy makes it and what it was tested for.
None of this is legal advice, and state pharmacy rules vary.
SS-31 vs MOTS-c
The two are often grouped as "mitochondrial peptides," but they are very different:
SS-31 (elamipretide)
MOTS-c
Origin
Synthetic, designed in a lab
Made naturally from mitochondrial DNA
Main idea
Binds cardiolipin in the inner membrane
Metabolic signal that activates AMPK, mostly studied in mice
Human trials
Many, including Phase 3
First placebo-controlled trial still recruiting
FDA status
Approved as Forzinity for Barth syndrome only
Not approved. Covered by the October 2026 HHS compounding policy
Is there an approved treatment with stronger evidence for my goal than SS-31?
Would I be getting Forzinity, a compounded product or a "research use only" chemical? Who made it?
How would we know if it is working, and when would we stop?
Do my kidney function and allergy history change anything?
Which reactions should make me stop and call you, and how do I report them to FDA MedWatch?
How PeptIQ.io Helps
PeptIQ.io's Peptide Claim Auditor takes a link to an Instagram, TikTok, X or Reddit post and checks each peptide claim in it against published research. Use it on posts calling SS-31 a proven anti-aging or energy peptide. The COA checker and the COA reading guide explain what a lab report does and does not prove. If you and your clinician agree on a treatment, the PeptIQ app logs injections, rotates sites and keeps symptom notes on one timeline you can share. Injection-site reactions are the most common side effect, so site records matter. Community notes live on the SS-31 wiki page.
Talk to a Licensed Clinician
Talk to a licensed clinician before starting SS-31. For Barth syndrome or another mitochondrial disease, that means a metabolic or genetics specialist. For eye, heart or energy concerns, start with the clinician who manages that condition. Bring the product name, its label and any certificate of analysis, and report suspected reactions to FDA MedWatch.
Frequently Asked Questions
Q: What is SS-31 peptide?
A: SS-31 is elamipretide, a lab-made peptide of four amino acids that binds cardiolipin in the inner mitochondrial membrane. It is sold as the prescription drug Forzinity for Barth syndrome. It has also been called MTP-131 and Bendavia.
Q: Is SS-31 FDA approved?
A: Yes, as Forzinity (elamipretide) injection. FDA granted accelerated approval on September 19, 2025, only to improve muscle strength in people with Barth syndrome who weigh at least 30 kg. A confirmatory trial is underway. It is not approved for any other use.
Q: What are the benefits of SS-31?
A: The proven benefit is stronger knee muscles in Barth syndrome, the basis for accelerated approval. Placebo-controlled trials in mitochondrial myopathy, heart failure and dry macular degeneration did not meet their main goals, so claims about energy, anti-aging or performance are not supported by trial results.
Q: What are the side effects of SS-31?
A: The most common are injection-site reactions such as redness, pain, itching and bruising. The FDA label also warns about serious allergic reactions and notes rises in eosinophils, a type of white blood cell.
Q: Is a research SS-31 vial the same as Forzinity?
A: No. Forzinity is made and tested to FDA standards. FDA has called "SS-31" research products unapproved new drugs, and their identity, purity and sterility are not verified. SS-31 is also not covered by the October 2026 HHS compounding policy.
Q: What is the half-life of SS-31?
A: The Forzinity label does not state a half-life. It says blood levels peak within about an hour of an injection under the skin and the drug is cleared by the kidneys within about two days, with higher exposure when kidney function is reduced.
Shirley M. Elamipretide: first approval. Drugs. 2026. PubMed 41335372
Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014. PubMed 24117165
Thompson WR, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome. Genet Med. 2021. PubMed 33077895
Thompson WR, et al. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet Med. 2024. PubMed 38602181
Karaa A, et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology. 2023. PubMed 37268435
Butler J, et al. Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: the PROGRESS-HF phase 2 trial. J Card Fail. 2020. PubMed 32068002
Ehlers JP, et al. ReCLAIM-2: a randomized phase II clinical trial evaluating elamipretide in age-related macular degeneration. Ophthalmol Sci. 2025. PubMed 39605874
Karanjia R, Sadun AA. Elamipretide topical ophthalmic solution for the treatment of subjects with Leber hereditary optic neuropathy: a randomized trial. Ophthalmology. 2024. PubMed 37923251
Roshanravan B, et al. In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial. PLoS One. 2021. PubMed 34264994
This article is educational content from PeptIQ.io. It is not medical advice. Talk with a licensed clinician before starting, stopping, or changing any peptide, medication, or injection practice.
For clinics: running peptide or GLP-1 programs for patients? See PeptIQ.io for providers: protocol templates, a patient app, and adherence tracking in one console.